Altogether, activating NOTCH1 mutations and related genetic events have been reported in at least 60–70% of primary T-ALL cases, consistent with a dominant oncogenic function of Notch signalling in this disease. This evidence concerns the gene NOTCH1 and acute lymphoblastic leukemia.